My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.950 UNCHANGED
Official Closing Price Updated: 8:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 217,589
Open 1.950
Bid (Size) 1.910 (5)
Ask (Size) 1.940 (5)
Prev. Close 1.950
Today's Range 1.900 - 1.965
52wk Range 1.120 - 7.000
Shares Outstanding 5,847,955
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results. 
Via Benzinga
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100%... 
Via Newsfile

Performance

YTD
-53.3%
-53.3%
1 Month
-11.4%
-11.4%
3 Month
+16.1%
+16.1%
6 Month
+24.2%
+24.2%
1 Year
-35.4%
-35.4%

More News

Read More
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Via Newsfile
Earnings Outlook For OS Therapies
Via Benzinga
OS Therapies to Participate in Fall 2025 Conferences and Events
Via Newsfile
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Via Newsfile
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
Via Newsfile
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Via Newsfile
Topics Death
Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)
Via Newsfile
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
Via Newsfile
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
Via Newsfile
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
Via Newsfile
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
Via Newsfile
OS Therapies Terminates Equity Line of Credit
Via Newsfile
Os Therapies Posts Wider Loss in Q2
Via The Motley Fool
Topics Intellectual Property
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
Via Newsfile
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
Via Newsfile
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Via Newsfile
Topics Artificial Intelligence Regulatory Compliance
OS Therapies Provides Clinical & Global Regulatory Updates
Via Newsfile
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
From OS Therapies
Via Business Wire
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
From OS Therapies
Via Business Wire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
Via FinancialNewsMedia
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
From OS Therapies
Via Business Wire

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.950
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 10/15/25 08:00 PM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 11.40M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 11M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.